CYDY - CytoDyn gets first purchase order from Chiral Pharma for use of leronlimab

CytoDyn ([[CYDY]]) announces that Chiral Pharma in the Philippines placed its first purchase order for leronlimab under a Compassionate Special Permit (“CSP”) to treat critically ill COVID-19 patients in the Philippines.The company expects to recognize revenues related to this purchase order upon fulfillment of the purchase order and the terms of the agreement.The U.S. FDA has granted CytoDyn "Fast Track" designation to explore two potential indications using leronlimab to treat Human Immunodeficiency Virus ((HIV)) and metastatic cancer.  CytoDyn's Brazilian distribution partner, Biomm S.A. plans to submit an authorization request to the Brazilian regulatory agency in the next few days to conduct two Phase 3 clinical trials of leronlimab in Brazil for COVID-19, the company said last week.

For further details see:

CytoDyn gets first purchase order from Chiral Pharma for use of leronlimab